Cite
HARVARD Citation
Schreiber, S. et al. (n.d.). OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. Journal of Crohn's and colitis. pp. S026-S027. [Online].